Table 1.
Characteristics of patients with metastasis
| Patient No. | Sex | Age at diagnosis, years | Histology | TNM | b-Tg2GICMA, ng/ml | s-Tg, ng/ml | Diagnosis of metastasis |
|---|---|---|---|---|---|---|---|
| 1 | F | 29 | DSPTC | T1N0M0 | <0.1 | <1.0 | positive US + FNAC |
| 2 | F | 35 | CPTC | T1N0M0 | <0.1 | 1.1 | positive US + FNAC 2 years after s-Tg |
| 3 | F | 26 | CPTC | T1N0M0 | <0.1 | 1.7 | positive US + FNAC 4 years after s-Tg |
| 4 | M | 36 | TCPTC | T3N1bM0 | <0.1 | 5.6 | positive WBS after therapeutic 131I activity (outside the TB) |
| 5 | F | 48 | CPTC | T3N1aM0 | 0.3 | 1.4 | positive US + FNAC 2 years after s-Tg |
| 6 | F | 27 | FVPTC | T1N1bM0 | 0.3 | 4.2 | positive WBS after therapeutic 131I activity (mediastinum) |
| 7 | F | 24 | CPTC | T3N1aM0 | 0.5 | 5.6 | positive WBS after therapeutic 131I activity (outside the TB) |
| 8 | F | 46 | FVPTC | T3N1aM0 | 0.3 | 7.5 | positive WBS after therapeutic 131I activity (outside the TB) |
| 9 | F | 32 | FVPTC | T2N0M0 | 0.8 | 7.6 | positive US + FNAC |
| 10 | F | 49 | CPTC | T2N1aM0 | 0.4 | 7.6 | positive WBS after therapeutic 131I activity (outside the TB) |
| 11 | F | 19 | CPTC | T2N1bM0 | 0.5 | 11.4 | positive US + FNAC |
| 12 | F | 48 | CPTC | T1N0M0 | 1.5 | 11.4 | positive US + FNAC |
| 13 | F | 35 | DSPTC | T3N1aM0 | 0.6 | 16.0 | positive WBS after therapeutic 131I activity (mediastinum) |
| 14 | F | 45 | CPTC | T2N1bM0 | 1.3 | 33.1 | positive WBS after therapeutic 131I activity (outside the TB) |
| 15 | F | 56 | CPTC | T1N0M0 | 1.5 | 48.3 | positive US + FNAC |
F = Female; M = male; CPTC = classical papillary thyroid carcinoma; FVPTC = follicular variant of PTC; TCPTC = tall cell PTC; DSPTC = diffuse sclerosing PTC; TB = thyroid bed; out TB = outside thyroid bed; FNAC = fine needle aspiration cytology.